Infectious Disease Research Institute, Seattle, Washington, USA.
Nat Med. 2013 Dec;19(12):1597-608. doi: 10.1038/nm.3409. Epub 2013 Dec 5.
Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases.
新型佐剂配方的疫苗越来越多地进入到高级开发和许可阶段,为满足以前未满足的临床需求提供了新工具。然而,由于可制造性、稳定性、效力不足、不可接受的耐受性水平或安全性问题等因素,许多佐剂在产品开发过程中失败。本综述概述了佐剂在当前和未来疫苗中的潜在益处,并描述了佐剂的配方和作用机制的重要性。此外,我们强调了在有效佐剂的临床开发中安全性方面的考虑因素和其他关键方面,这将有助于促进针对破坏性传染病的下一代有效疫苗。
Nat Med. 2013-12-5
Drug Discov Today. 2009-3-5
Arch Pharm Res. 2017-10-13
Expert Rev Vaccines. 2003-4
Expert Rev Vaccines. 2017-5
Curr Opin Immunol. 2011-4-19
Expert Rev Vaccines. 2018-3-30
Front Immunol. 2018-12-13
J Clin Invest. 2016-3-1
Vaccines (Basel). 2025-7-26
J Funct Biomater. 2025-8-2
Front Drug Deliv. 2023-4-26
Front Drug Deliv. 2023-11-6
Nat Aging. 2025-8
NPJ Vaccines. 2025-8-1
Lancet Infect Dis. 2013-5
Hum Vaccin Immunother. 2013-5-31